Početna stranicaFTRE • NASDAQ
add
Fortrea Holdings Inc
19,73 $
Poslije radnog vremena:(0,00 %)0,00
19,73 $
Zatvoreno: 22. stu, 16:16:10 GMT -5 · USD · NASDAQ · Odricanje od odgovornosti
Preth. zaklj. cijena
19,50 $
Dnevni raspon
19,18 $ - 20,14 $
Godišnji raspon
16,53 $ - 41,02 $
Tržišna kapitalizacija
1,77 mlr. USD
Prosječna količina
1,32 mil.
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
NASDAQ
U vijestima
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
(USD) | ruj 2024.info | Godišnja promjena |
---|---|---|
Prihod | 674,90 mil. | −5,45 % |
Operativni troškovi | 157,50 mil. | 21,53 % |
Neto dohodak | −27,90 mil. | −99,29 % |
Neto profitabilnost | −4,13 | −110,71 % |
Zarada po dionici | 0,23 | −4,17 % |
EBITDA | 12,00 mil. | −72,22 % |
Efektivna porezna stopa | 48,32 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
(USD) | ruj 2024.info | Godišnja promjena |
---|---|---|
Gotovinska i kratkoročna ulaganja | 105,30 mil. | −4,01 % |
Ukupna imovina | 3,66 mlr. | −15,13 % |
Ukupne obveze | 2,15 mlr. | −18,01 % |
Ukupni kapital | 1,51 mlr. | — |
Dionice u optjecaju | 89,70 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 1,16 | — |
Povrat imovine | −0,64 % | — |
Povrat kapitala | −0,85 % | — |
Tok novca
Neto promjena novca
(USD) | ruj 2024.info | Godišnja promjena |
---|---|---|
Neto dohodak | −27,90 mil. | −99,29 % |
Gotovina od poslovanja | −2,40 mil. | −226,32 % |
Gotovina iz ulaganja | −8,10 mil. | −400,00 % |
Gotovina iz financiranja | −14,00 mil. | −81,82 % |
Neto promjena novca | −20,90 mil. | −309,80 % |
Slobodan tok novca | −19,35 mil. | −269,37 % |
Više
Fortrea Holdings Inc. is a contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in 90 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries.
Its primary business is handling all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, and post-approval services. It handles regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. It focuses on oncology, central nervous system and neurodegenerative, rare diseases, and cell and gene therapies. In the five years ending in 2023, it conducted more than 5,850 clinical trials involving over 1 million subjects. It also conducted over 600 studies for medical device companies.
The company is one of the largest participants in the international primate trade and has been criticized for its animal testing practices, most specifically animal testing on non-human primates. Wikipedia
Glavni izvršni direktor
Osnovano
tra 1996
Web-lokacija
Zaposlenici
15.500